Summary of findings 4. Fluoxetine compared to amineptine.
| Fluoxetine compared to amineptine | ||||||
| Patient or population: patients with depression Settings: in‐ and outpatients Intervention: fluoxetine Comparison: amineptine | ||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Assumed risk | Corresponding risk | |||||
| Amineptine | Fluoxetine | |||||
|
Failure to respond (reduction ≥ 50% on HDRS) |
719 per 1000 | 486 per 1000 (249 to 727) | OR 0.37 (0.13 to 1.04) | 63 (1 study) | ⊕⊕⊕⊝ moderate1 | |
|
Endpoint score (HDRS or MADRS) |
The mean endpoint score in the intervention groups was 0 standard deviations higher (0 to 0 higher) | 0 (0) | No data available on this outcome | |||
| Failure to complete ‐ total ‐ | 210 per 1000 | 140 per 1000 (43 to 370) | OR 0.61 (0.17 to 2.21) | 232 (2 studies) | ⊕⊕⊕⊝ moderate1 | |
| Failure to complete ‐ inefficacy ‐ | 94 per 1000 | 97 per 1000 (19 to 366) | OR 1.04 (0.19 to 5.57) | 63 (1 study) | ⊕⊕⊕⊝ moderate1 | |
| Failure to complete ‐ side effects ‐ (Copy) | 84 per 1000 | 46 per 1000 (3 to 418) | OR 0.52 (0.03 to 7.82) | 232 (2 studies) | ⊕⊕⊕⊝ moderate1 | |
| *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; OR: Odds ratio; | ||||||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. | ||||||
1 Limitations in studies designs: no details on randomisation procedures and allocation concealment. Blinding stated but not tested.